A promising future in cancer immunotherapy : Oncolytic viruses
Copyright © 2023 Elsevier B.V. All rights reserved..
Alongside the conventional methods, attention has been drawn to the use of immunotherapy-based methods for cancer treatment. Immunotherapy has developed as a therapeutic option that can be more specific with better outcomes in tumor treatment. It can boost or regulate the immune system behind the targeted virotherapy. Virotherapy is a kind of oncolytic immunotherapy that investigated broadly in cancer treatment in recent decades, due to its several advantages. According to recent advance in the field of understanding cancer cell biology and its occurrence, as well as increasing the knowledge about conditionally replicating oncolytic viruses and their destructive function in the tumor cells, nowadays, it is possible to apply this strategy in the treatment of malignancies. Relying on achievements in clinical trials of oncolytic viruses, we can certainly expect that this therapeutic perception can play a more central role in cancer treatment. In cancer treatment, combination therapy using oncolytic viruses alongside standard cancer treatment methods and other immunotherapy-based treatments can expect more promising results in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:960 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 960(2023) vom: 05. Dez., Seite 176063 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seyed-Khorrami, Seyed-Mahmood [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR-T therapy |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 27.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejphar.2023.176063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362913196 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362913196 | ||
| 003 | DE-627 | ||
| 005 | 20231226092231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2023.176063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM362913196 | ||
| 035 | |a (NLM)37797673 | ||
| 035 | |a (PII)S0014-2999(23)00575-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seyed-Khorrami, Seyed-Mahmood |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A promising future in cancer immunotherapy |b Oncolytic viruses |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Alongside the conventional methods, attention has been drawn to the use of immunotherapy-based methods for cancer treatment. Immunotherapy has developed as a therapeutic option that can be more specific with better outcomes in tumor treatment. It can boost or regulate the immune system behind the targeted virotherapy. Virotherapy is a kind of oncolytic immunotherapy that investigated broadly in cancer treatment in recent decades, due to its several advantages. According to recent advance in the field of understanding cancer cell biology and its occurrence, as well as increasing the knowledge about conditionally replicating oncolytic viruses and their destructive function in the tumor cells, nowadays, it is possible to apply this strategy in the treatment of malignancies. Relying on achievements in clinical trials of oncolytic viruses, we can certainly expect that this therapeutic perception can play a more central role in cancer treatment. In cancer treatment, combination therapy using oncolytic viruses alongside standard cancer treatment methods and other immunotherapy-based treatments can expect more promising results in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CAR-T therapy | |
| 650 | 4 | |a Cancer treatment | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Oncolytic virus | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 4 | |a Tumor microenvironment | |
| 700 | 1 | |a Azadi, Arezou |e verfasserin |4 aut | |
| 700 | 1 | |a Rastegarvand, Nasrin |e verfasserin |4 aut | |
| 700 | 1 | |a Habibian, Ala |e verfasserin |4 aut | |
| 700 | 1 | |a Soleimanjahi, Hoorieh |e verfasserin |4 aut | |
| 700 | 1 | |a Łos, Marek J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 960(2023) vom: 05. Dez., Seite 176063 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:960 |g year:2023 |g day:05 |g month:12 |g pages:176063 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2023.176063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 960 |j 2023 |b 05 |c 12 |h 176063 | ||